Zhejiang Cheng Yi Pharmaceutical Co Ltd Market Cap ($451.27 Million)
Market Cap & Net Worth: Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811)
Zhejiang Cheng Yi Pharmaceutical Co Ltd market cap. Zhejiang Cheng Yi Pharmaceutical Co Ltd (SHG:603811) has a market capitalization of $451.27 Million (CN¥3.08 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #12438 globally and #3625 in its home market, demonstrating a 1.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Cheng Yi Pharmaceutical Co Ltd's stock price CN¥6.73 by its total outstanding shares 458226048 (458.23 Million). Also see 603811 cash flow conversion for how efficiently the company converts equity into cash flow.
Zhejiang Cheng Yi Pharmaceutical Co Ltd Market Cap History (2017–2026)
Zhejiang Cheng Yi Pharmaceutical Co Ltd market cap history from 2017 to 2026. Data shows growth from $466.44 Million to $451.27 Million (2.62% CAGR). Check Zhejiang Cheng Yi Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Zhejiang Cheng Yi Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Cheng Yi Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 603811 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.87x
Zhejiang Cheng Yi Pharmaceutical Co Ltd's market cap is 0.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.61x
Zhejiang Cheng Yi Pharmaceutical Co Ltd's market cap is 3.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $466.44 Million | $340.89 Million | $69.24 Million | 1.37x | 6.74x |
| 2018 | $360.84 Million | $545.77 Million | $96.91 Million | 0.66x | 3.72x |
| 2019 | $581.74 Million | $681.23 Million | $131.39 Million | 0.85x | 4.43x |
| 2020 | $745.72 Million | $758.13 Million | $165.14 Million | 0.98x | 4.52x |
| 2021 | $747.97 Million | $693.96 Million | $170.80 Million | 1.08x | 4.38x |
| 2022 | $657.04 Million | $654.97 Million | $161.58 Million | 1.00x | 4.07x |
| 2023 | $695.34 Million | $671.63 Million | $162.90 Million | 1.04x | 4.27x |
| 2024 | $517.65 Million | $714.37 Million | $200.70 Million | 0.72x | 2.58x |
| 2025 | $704.06 Million | $812.35 Million | $195.12 Million | 0.87x | 3.61x |
Competitor Companies of 603811 by Market Capitalization
Companies near Zhejiang Cheng Yi Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811) total assets for a full breakdown of the balance sheet.
Key companies related to Zhejiang Cheng Yi Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Zhejiang Cheng Yi Pharmaceutical Co Ltd (2017–2026)
Market capitalization of Zhejiang Cheng Yi Pharmaceutical Co Ltd from 2017 to today. Between 2017 and today, Zhejiang Cheng Yi Pharmaceutical Co Ltd's market cap moved from $466.44 Million to $ 451.27 Million, with a yearly change of 2.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥451.27 Million | -35.90% |
| 2025 | CN¥704.06 Million | +36.01% |
| 2024 | CN¥517.65 Million | -25.55% |
| 2023 | CN¥695.34 Million | +5.83% |
| 2022 | CN¥657.04 Million | -12.16% |
| 2021 | CN¥747.97 Million | +0.30% |
| 2020 | CN¥745.72 Million | +28.19% |
| 2019 | CN¥581.74 Million | +61.22% |
| 2018 | CN¥360.84 Million | -22.64% |
| 2017 | CN¥466.44 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Zhejiang Cheng Yi Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $451.27 Million USD |
| MoneyControl | $451.27 Million USD |
| MarketWatch | $451.27 Million USD |
| marketcap.company | $451.27 Million USD |
| Reuters | $451.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, cap… Read more